PHCentral RSS - rss FIRE feed Thu, 24 Apr 2014 04:04:30 GMT Persistent Pulmonary Hypertension in the Newborn Found To Be Tied To SSRI Anti-Depressants In New Study April 22, 2014
A group of researchers ... performed a total of 7 meta-analyses based on available data resources, determining the effects of the maternal anti-depressant Selective Serotonin Reuptake Inhibitor (SSRI) on pregnancy and child health. She and her research team concluded that usage of SSRIs during the third trimester of pregnancy led to a low but significant risk of Persistent Pulmonary Hypertension in the Newborn (PPHN). It is to be noted that no such relationship was found during the early stages of pregnancy.]]>
'Usual' Sodium Intake Seems to Hit Right Balance April 21, 2014
Salt <--> Blood pressure seems to continue to be controversial.]]>
Aspirin Tied to Fewer Deaths in COPD Flares April 20, 2014 Treat-to-Target the New Goal in Lupus April 20, 2014 Obstructive Sleep Apnea May Increase Osteoporosis Risk April 20, 2014 Journal of Clinical Endocrinology and Metabolism.]]> NSAIDs Double Bleeding Risk With Anticoagulants for DVT/PE April 19, 2014 JAMA Internal Medicine.]]> High-Risk Adults Often Do Not Seek Early Treatment for Flu Symptoms April 19, 2014 Journal of Infectious Diseases.]]> PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension April 18, 2014 Nocturnal oxygen improves 6min-walk by 25m vs. placebo in PAH patients with SDB April 18, 2014 Actelion Beats First-Quarter Earnings Expectations April 17, 2014 Japanese Pulmonary Arterial Hypertension Patients Fare Better On PAH Drugs, according to Study April 17, 2014 Among these treated patients, 93% received prostacyclin analogs, 68% endothelia receptor antagonists, and 52% phosphodiesterase type 5 inhibitors. Overall, 75% of the patients were  treated with some form of combination therapy...]]> Chinese Herb Proves Effective in Rheumatoid Arthritis (RA) April 16, 2014
At 6 months, 46.4% of patients receiving methotrexate had improved by at least 50% on the American College of Rheumatology (ACR50) criteria, as had 55.1% of those receiving extracts Tripterygium wilfordii Hook F (TwHF) and 76.8% of those given both, according to Xuan Zhang, MD, of the Chinese Academy of Medical Sciences in Beijing, and colleagues...]]>
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. April 15, 2014 The homozygous VHLD126N missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension. April 15, 2014 Use of inhaled iloprost in children with pulmonary hypertension. April 15, 2014 Bayer Launches Educational Website For CTEPH April 15, 2014 Astronaut hearts shift in microgravity April 14, 2014
Small Company develops therapeutic DNA for PAH April 14, 2014 Stem Cells Seen as Promising in Lupus April 13, 2014 Focus on Chronic Illness Drugs Needed April 13, 2014 What the Tamiflu saga tells us about drug trials and big pharma April 12, 2014 Docosatetraenoyl LPA is Elevated in Exhaled Breath Condensate in Idiopathic Pulmonary Fibrosis April 12, 2014 Study Suggests Link Between Viagra And Melanoma April 11, 2014 Prime Time: When Docs Require Cash on Delivery;_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&eun=g425186d0r&userid=425186& April 10, 2014 Triple therapy shows promise for severe PAH April 10, 2014 ICU Survivors Prone to Some Depression Symptoms;_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&eun=g425186d0r&userid=425186& April 9, 2014 Pre-Capillary Pulmonary Hypertension Common in Severe Heart Failure April 8, 2014 Use of age-adjusted D-dimer levels to exclude lung blood clots April 7, 2014 Relaxed blood pressure guidelines cut millions from needing medication April 7, 2014 Pulmonary Hypertension in Systemic Lupus Erythematosus April 6, 2014 Developments in COPD April 6, 2014 Implementing Lessons Learned From Previous Bronchial Biopsy Trials in a New Randomized Controlled COPD Biopsy Trial With Roflumilast April 5, 2014 Stem cell scientist guilty of falsifying data April 5, 2014 FDA: Celgene's Otezla OK for Psoriatic Arthritis April 5, 2014 - Helen P]]> Sanford Health Launches New Pulmonary Hypertension Clinic Service (Sioux Falls, SD) April 4, 2014
Sanford Pulmonary Hypertension Clinic is the first of its kind in South Dakota. The primary goal of this new clinic is to use the combined expertise of the medical team to extend the length and quality of life for pulmonary hypertension patients. 

This new service focuses on a multidisciplinary approach consisting of a pulmonologist, a cardiologist, specially trained nurses, respiratory therapists and pharmacists. Sanford Heart cardiologist, Dr. Orvar Jonsson and Sanford Health pulmonologist, Dr. John Yu will lead the members of this multidisciplinary team and review each patient’s individual case to create a specific care plan for each unique case.]]>
Pulmonary Hypertension Therapies Could Improve, Thanks To New Yale Study April 3, 2014
The new study, which was published in the February 27th edition of Cell Reports, highlights the researchers’ efforts to learn more about the specific cellular mechanisms that occur behind the scenes in terms of the way that cells are organized in pulmonary arteries in patients who have pulmonary hypertension. It is this organization of cells that has been found to directly lead to patients being short of breath and fatigued

”For the first time, we understand which cells are responsible and the cellular processes underlying their recruitment,” and adding that, “We looked at the mechanism involved in how these cells migrate along blood vessels.”

The result of diseases such as pulmonary hypertension and other vascular disorders such as atherosclerosis is the development of excess smooth muscle accumulation in vascular structures in the lungs. Healthy lungs have patterns that are similar is design to that of tree branches, and the smallest blood vessels that branch out from these structures normally do not have a muscular coating. In the case of PH, however,even these small blood vessel branches become muscularized, which in turn leads to labored breathing.]]>
Guidelines Developed for Pulmonary HTN in Sickle Cell Dz April 3, 2014
Elizabeth S. Klings, MD, from Boston University, and colleagues produced evidence-based recommendations relating to management of adult patients with pulmonary hypertension in SCD.]]>
Pulmokine Awarded $1.5 Million Stage B VITA Contract to Advance Inhaled Kinase Inhibitors for Pulmonary Arterial Hypertension April 2, 2014
"Preclinical results of our novel, inhaled PDGF receptor inhibitor are quite compelling, showing a meaningful decrease in pulmonary pressures in animal models of PAH. Importantly, by interfering with the PDGF receptor pathway, our candidates have the potential to address an underlying cause of PAH, not merely to alleviate its symptoms," said Dr. Zisman, the CEO of Pulmokine. "The VITA contract will allow us to complete additional studies required to advance our lead candidate into Phase 1 clinical trials in patients with PAH." - See more at:]]>
Patients with Severe Pulmonary Hypertension Benefit from TAVR Despite Increased Mortality April 1, 2014 Pulmonary arterial hypertension common among Sjogrens Syndrome patientsögrens-syndrome-patients April 1, 2014
A recent study found that pulmonary arterial hypertension (high blood pressure in the arteries in the lungs) is more common among patients with Primary Sjögren’s Syndrome.

The researchers discovered that the patients with pulmonary arterial hypertension were female, younger and had had Primary Sjögren’s Syndrome for a shorter amount of time.

Read more:]]>
FDA Clarifies Its Position on Revatio Use in Children March 31, 2014
In August 2012, the Revatio drug label was revised with an added warning that stated “use of Revatio, particularly of chronic use, is not recommended in children.” This recommendation was based on data from a long-term clinical trial in pediatric patients that showed increasing mortality with increasing Revatio doses.

Although Revatio is approved only to treat PAH in adults, healthcare providers must consider whether the benefits of treatment are likely to outweigh the risks for each patient. The Agency noted that there may be circumstances in which the benefit-risk profile of Revatio may be acceptable in individual children, if other treatment options are limited.

The recommendation from August 2012 was not intended to suggest that Revatio should never be prescribed for pediatric use.
Adempas (Riociguat) wins EU-Approval for PAH und CTEPH March 31, 2014 Bosentan Comes up Empty in Postmarket PAH Trial March 30, 2014 Age-Adjusted D-dimer Cutoff to Rule Out PE Ready for Prime Time March 30, 2014 IPAH cured in a single case? March 29, 2014
This is the final statement of a case report, where a woman received a comparably low dose radiation treatment and the PVR (alias PAR) went down from more than 1300 to 400 dyn*s*cm-5 within 7 1/2 months after the mentioned radiation threatment, which deleted pulmonary arterial nerves and rose VIP level. 

Click headline to find the abstract and then click the downlord button to get a full text PDF-download. 
'Bendopnea': A New Symptom to Help Spot Sicker HF Patients? March 29, 2014 PCORI’s Research Will Answer Patients’ Real-World Questions March 29, 2014 Sleep apnea: What you need to know March 27, 2014
Sleep apnea is increasing among men and women. Recent data showed that among adults 30 to 70 years of age, 13 percent of men and 6 percent of women have moderate to severe sleep apnea. Unfortunately, as many as 85 percent of people who have sleep apnea remain undiagnosed and untreated...
Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension March 27, 2014 New guidelines for sickle cell disease and PAH March 26, 2014 Elizabeth S. Klings, M.D., from Boston University, and colleagues produced evidence-based recommendations relating to management of adult patients with pulmonary hypertension in SCD.
According to the report, decision making should be guided by stratification of mortality risk. For patient..]]>
United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment March 26, 2014 Bayer initiates trial to assess riociguat for resistant pulmonary arterial hypertension{9b91ed3a-e357-4a64-bf21-76589ebe0dba}/bayer-initiates-trial-to-assess-riociguat-for-resistant-pulmonary-arterial-hypertension March 26, 2014
The open-label, multicenter, international pilot study will assess the soluble guanylate cyclase stimulator riociguat (Adempas) in patients with pulmonary arterial hypertension who are resistant to treatment with phosphodiesterase-5 (PDE5) inhibitors, according to a press release.

The trial will include approximately 60 patients with PAH who received at least 3 months of prior treatment with sildenafil (Viagra/Revatio, Pfizer) or tadalafil (Cialis, Lilly) and did not demonstrate sufficient clinical responsiveness to PDE5 inhibitor treatment. Participants will receive 24 weeks of riociguat..]]>
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: Clinical associations. March 25, 2014
Endothelin receptor antagonism reduces serum uric acid in PAH patients, and this reduction is associated with improved survival and longer TtCW. Further prospective studies are needed to investigate the pathogenic role of serum uric acid in PAH and its prognostic potential.

Regulation of pulmonary inflammation by mesenchymal cells. March 25, 2014